Unaudited Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities:
Net loss	$ (13,759,298)	$ (16,480,817)
Adjustment to reconcile net loss to net cash used in operating activities:
Stock based compensation	1,803,014	2,343,859
Interest accrued on note receivable	(27,219)	(82,895)
Change in fair value of note receivable	560,473	114,870
Write-off of construction-in-process		747,348
Depreciation and amortization	421,794	371,814
Changes in operating assets and liabilities:
Research and development tax incentive receivable	125,899	(211,785)
Prepaid assets and other current assets	1,100,238	1,416,302
Accounts payable	608,039	66,910
Accrued liabilities	702,898	(4,430)
Deferred revenue	149,698	(50,000)
Operating lease obligation	(62,851)	(55,764)
Net cash used in operating activities	(8,377,315)	(11,824,588)
Cash flows from investing activities:
Purchases of property and equipment		(48,359)
Net cash used in investing activities		(48,359)
Cash flows from financing activities:
Sale of common stock in public offering, net of offering costs		5,064,722
Sales of common stock through ATM	526,867	25,272
Payment of offering costs in connection with ATM	(84,464)	(77,149)
Payment of deferred offering costs	(20,000)
Proceeds from issuance of common stock for pre-funded warrant exercises	19
Sales of common stock and warrants through offerings, net of offering costs	5,102,519
Net cash provided by (used in) financing activities	5,524,941	5,012,845
Effect of exchange rate changes on cash and cash equivalents	(19,237)	(26,458)
Net change in cash and cash equivalents	(2,871,611)	(6,886,560)
Cash and cash equivalents at beginning of period	5,478,113	16,612,315
Cash and cash equivalents at end of period	2,606,502	9,725,755
Supplemental disclosure of cash flow information:
Cash paid for income taxes
Cash paid for interest	23,914
Supplemental disclosure of non-cash investing and financing activities:
Conversion of note receivable into common stock of Augmenta	1,776,746
Exchange of Augmenta common stock for common stock of Vaxanix	1,776,746
Deferred offering costs included in accounts payable	$ 75,322